IGF-1 DES, formally designated Des(1-3)IGF-1 (CAS 112603-35-7), is a truncated 67-amino acid analogue of human insulin-like growth factor 1 (IGF-1). With a molecular weight of 7371.48 g/mol, IGF-1 DES corresponds to residues 4-70 of native IGF-1. The absence of the N-terminal tripeptide Gly-Pro-Glu is the defining structural feature of Des(1-3)IGF-1 and is considered central to its altered IGFBP binding characteristics. Produced via solid-phase peptide synthesis, IGF-1 DES acts as an agonist at the IGF-1 receptor (IGF-1R).

Des(1-3)IGF-1 has been extensively investigated in preclinical cell biology and growth factor research for the functional consequences of its N-terminal truncation. The removal of the Gly-Pro-Glu tripeptide has been documented in published studies to reduce binding affinity for insulin-like growth factor-binding proteins (IGFBPs), proteins that regulate IGF-1 bioavailability and tissue distribution in native physiology. In vitro studies in L6 rat myoblast and related muscle-derived cell preparations have examined IGF-1 DES’s receptor activation and mitogenic signalling, characterising binding properties and biological potencies at the IGF-1 receptor relative to native IGF-1 [1]. Comparative preclinical studies have also examined IGFBP interaction profiles and receptor binding kinetics of Des(1-3)IGF-1 relative to native IGF-1, with published findings documenting that IGFBP-dependent inhibition of receptor-mediated biological activity is substantially attenuated for Des(1-3)IGF-1, making it a key reference compound in IGF-1 analogue research [2].

IGF-1 DES is manufactured in a cGMP compliant laboratory to a guaranteed purity of 98% or above. Every batch is independently tested using HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

Editorial Team

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed and approved 14 June 2026

View credentials →